Two experimental treatments presented at a San Diego cancer conference are generating rare optimism for patients with pancreatic cancer, one of oncology's deadliest diagnoses. Revolution Medicines and a partnership between BioNTech and Roche's Genentech unit unveiled early but promising results from small clinical trials.

Revolution Medicines' drug daraxonrasib achieved what oncologists called unprecedented results, doubling patient survival to over 13 months compared to less than seven months with standard chemotherapy. Former Senator Ben Sasse, diagnosed with terminal pancreatic cancer late last year, said the drug shrunk his tumors. The company plans to seek regulatory approval soon.

An experimental mRNA vaccine from BioNTech and Genentech showed that seven of eight patients whose immune systems responded to the treatment were alive up to six years after receiving the last dose. The findings arrive during a challenging period for mRNA technology, as the Trump administration has made policy changes hostile to the approach under Health Secretary Robert F. Kennedy Jr.

Pancreatic cancer kills more than 50,000 Americans annually, with only 13% surviving five years. Revolution Medicines' shares surged on the news, reflecting investor enthusiasm for a market with virtually no effective treatment options.